rejevity bpc 157 50mg BPC-157 – Research Peptide BPC 157 - Rejüv Peptides

Intended use

Studies with similar compounds show 60 to 70% of lost weight returning within 12 to 18 months of stopping treatment

This is in agreement with a recent study reporting a decreased number of duodenal serotonin containing endocrine cells in FD patients ( Several 5-HT receptor agonists/antagonists, such as cisapride (5-HT4 agonist, 5-HT2, and 5-HT3 antagonist), tegaserod (5-HT4 and 5-HT1 agonist, 5-HT2a/b antagonist), mosapride (5-HT4 agonist, 5-HT3 antagonist) and revexepride (5-HT4 agonist) have been evaluated for the treatment of dyspepsia and gastroparesis, although not all studies show efficacy (114116)

This means that a peptide with a 2-hour half-life administered three times daily will reach steady-state within approximately 10 hours, while a peptide with a 7-day half-life like Semaglutide requires roughly 35 days to reach steady state with weekly dosing

Cost considerations favor single peptide approaches when budget constraints exist